Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Summary
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.
Official title: Conducting an Early Phase Clinical Trial to Assess for HPV Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests the Potential for Clinical Benefits of HPV Patients
Key Details
Gender
FEMALE
Age Range
24 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-04-28
Completion Date
2026-09-28
Last Updated
2025-05-13
Healthy Volunteers
No
Conditions
Interventions
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
By the percutaneous route with the multiple puncture device - 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix
Locations (1)
Medicine Invention Design, Inc.
Rockville, Maryland, United States